Influence ofCYP2C9andVKORC1on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans
- 1 May 2008
- journal article
- research article
- Published by Future Medicine Ltd in Pharmacogenomics
- Vol. 9 (5), 511-526
- https://doi.org/10.2217/14622416.9.5.511
Abstract
Aims: The influence of CYP2C9 and VKORC1 on warfarin dose, time to target International Normalized Ratio (INR), time to stabilization, and risk of over-anticoagulation (INR: >4) was assessed after adjustment for clinical factors, intraindividual variation in environmental factors and unobserved heterogeneity. Materials & Methods: Common CYP2C9 and VKORC1 polymorphisms were assessed in 302 European–Americans and 273 African–Americans receiving warfarin. Race-stratified multivariable analyses evaluated the influence of CYP2C9 and VKORC1 on warfarin response. Results & Conclusion:CYP2C9 and VKORC1 accounted for up to 30% of the variability in warfarin dose among European–Americans and 10% among African–Americans. Neither CYP2C9 nor VKORC1 influenced the time to target INR or stabilization among patients of either race, and neither influenced the risk of over-anticoagulation among African–Americans. The risk of over-anticoagulation was higher among European–Americans with variant VKORC1 1173C/T (p < 0.01) and marginally significant among those with variant CYP2C9 (p = 0.08) genotype. Although CYP2C9 and VKORC1 genotyping can facilitate individualized initiation of warfarin dose in African and European–Americans, the ability to predict the risk of over-anticoagulation is inconsistent across race. Identification of other factors that can predict such risk consistently in a racially diverse group will facilitate individualized maintenance of warfarin therapy.Keywords
This publication has 65 references indexed in Scilit:
- CYP4F2 genetic variant alters required warfarin doseBlood, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillationThrombosis Research, 2007
- Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on WarfarinClinical Pharmacology & Therapeutics, 2007
- Influence of CYP2C9 genotype on warfarin dose among African–Americans and European–AmericansPersonalized Medicine, 2007
- Evaluation of Genetic Factors for Warfarin Dose PredictionClinical Medicine & Research, 2007
- Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapyBlood Cells, Molecules, and Diseases, 2006
- Association of warfarin dose with genes involved in its action and metabolismHuman Genetics, 2006
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseThe New England Journal of Medicine, 2005
- The underutilization of cardiacmedications of proven benefit, 1990 to 2002Journal of the American College of Cardiology, 2003